Moraxella (e.g., Moraxella Bovis, Etc.) Patents (Class 424/251.1)
  • Patent number: 10786562
    Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: September 29, 2020
    Assignee: ARNE FORSGREN AB
    Inventors: Arne Forsgren, Kristian Riesbeck
  • Patent number: 10745449
    Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 18, 2020
    Assignee: GlaxoSmithKline
    Inventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
  • Patent number: 9566323
    Abstract: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: February 14, 2017
    Assignee: Eyegene Inc.
    Inventors: Hong-Jin Kim, Na Gyong Lee, Yang-Je Cho, Jin-Wook Jang, Hyoung Jin Kim, Kwang Sung Kim
  • Patent number: 8895030
    Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: November 25, 2014
    Assignee: Arne Forsgren AB
    Inventors: Arne Forsgren, Kristian Riesbeck
  • Patent number: 8728491
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: May 20, 2014
    Assignee: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Patent number: 8697092
    Abstract: There are disclosed herein antigenic structures useful in producing vaccines against and compounds helpful in combating diseases caused by the bacterium Moraxella catarrhalis. Disclosed are specific structures of the carbohydrate molecules derived from genetically engineered strains of Moraxella catarrhalis, which when presented appropriately to the immune system will facilitate a functional immune response to the target core oligosaccharide region.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: April 15, 2014
    Inventors: Andrew D. Cox, James C. Richards
  • Patent number: 8323667
    Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: December 4, 2012
    Assignee: Arne Forsgren AB
    Inventors: Arne Forsgren, Kristian Riesbeck
  • Patent number: 8309327
    Abstract: The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: November 13, 2012
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Biemans, Karine Goraj, Emmanuel Mertens, Annick Vandercammen
  • Patent number: 8252901
    Abstract: In accordance with the present invention, a family of membrane fusion protein and polynucleotides encoding the proteins have been identified. The proteins and nucleotides are derived from the family Reoviridae. Two membrane fusion proteins have been isolated from reoviruses isolated from poikilothermic hosts: the p14 protein from reptilian reovirus (RRV) isolated from python, and the p16 protein from aquareovirus (AQV) isolated from salmon. The genes encoding these proteins have been cloned and sequenced. Analysis of the amino acid sequences of these proteins show that both lack the typical fusion peptide motif found in other membrane fusion proteins. Expression of these proteins in cells results in cell-cell fusion.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: August 28, 2012
    Assignee: Innovascreen, Inc.
    Inventor: Roy Duncan
  • Publication number: 20120020979
    Abstract: This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.
    Type: Application
    Filed: April 1, 2010
    Publication date: January 26, 2012
    Applicant: CORNELL UNIVERSITY
    Inventors: Andrea Cerutti, Kang Chen
  • Patent number: 8092811
    Abstract: The present invention relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present invention also provides peptides interacting with fibronectin, laminin and the complement system.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: January 10, 2012
    Assignee: Arne Forsgren AB
    Inventors: Arne Forsgren, Kristian Riesbeck
  • Patent number: 8084235
    Abstract: The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt.
    Type: Grant
    Filed: March 11, 2004
    Date of Patent: December 27, 2011
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Biemans, Karine Goraj, Emmanuel Mertens, Annick Vandercammen
  • Publication number: 20110280910
    Abstract: The present invention relates to a surface exposed protein, which can be detected in Moraxella catarrhalis, having an amino acid sequence as described in SEQ ID NO: 1, an apparent molecular weight of 200 kDa and a capacity of selectively binding membrane bound or soluble IgD, to an immunogenic or IgD-binding fragment of said surface exposed protein, and to an immunogenic and adhesive fragment of said surface exposed protein. DNA segments, vaccines, plasmids and phages, non human hosts, recombinant DNA molecules and plants, fusion proteins and polypeptides and fusion products are also described. A method of detecting IgD, a method of separating IgD, a method of isolation of a surface exposed protein of Moraxella catarrhalis and a method for treatment of an autoimmune disease are also disclosed.
    Type: Application
    Filed: June 8, 2011
    Publication date: November 17, 2011
    Applicant: ARNE FORSGREN ET AL.
    Inventors: Arne Forsgren, Kristian Riesbeck, Håkan Jansson
  • Publication number: 20110104207
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
    Type: Application
    Filed: April 16, 2010
    Publication date: May 5, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul CHARIFSON, David DEININGER, Joseph DRUMM, Anne-Laure GRILLOT, Yusheng LIAO, Patricia OLIVER-SHAFFER, Dean STAMOS
  • Patent number: 7846451
    Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to M. catarrhalis and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: December 7, 2010
    Assignee: Emergent Product Development Gaithersburg, Inc.
    Inventors: Kenneth Tucker, Ulrich F. Tillman
  • Publication number: 20100285064
    Abstract: The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.
    Type: Application
    Filed: May 5, 2010
    Publication date: November 11, 2010
    Applicant: SERUM INSTITUTE OF INDIA LTD.
    Inventors: Suresh Sakharam Jadhav, Bhushan Patwardhan, Manish Gautam
  • Publication number: 20100272758
    Abstract: The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.
    Type: Application
    Filed: January 19, 2007
    Publication date: October 28, 2010
    Applicant: Regents of the University of Michigan
    Inventors: Ronald Wesley Woodard, Timothy Charles Meredith, Parag Aggarwal
  • Patent number: 7811589
    Abstract: Provided is a method for stimulating in an individual an immune response against M. catarrhalis. The method is performed by administering to an individual a composition that contains at least one isolated M. catarrhalis protein in an amount effective to stimulate an immune response against M. catarrhalis in the individual. The M. catarrhalis proteins used in the method of the invention are M. catarrhalis proteins Msp22, Msp75, Msp78, Protein 28, Protein 99, Protein 238, and combinations thereof.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: October 12, 2010
    Assignee: The Research Foundation of State University of New York
    Inventors: Timothy F. Murphy, Alan J. Lesse, Charmaine Kirkham
  • Patent number: 7811590
    Abstract: This invention relates to recombinant bacterial outer membrane proteins comprising one or more LB1(f) peptides from surface-exposed loop 3 of MOMP P5 of non-typeable H. influenzae. Polynucleotides encoding these recombinant proteins are also covered. The invention also relates to a method of isolating the recombinant proteins and a vaccine composition for use in the treatment of Haemophilus influenzae infection.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: October 12, 2010
    Assignees: The Ohio State University Research Foundation, GlaxoSmithKline
    Inventors: Lauren O. Bakaletz, Francois-Xavier Jacques Berthet, Philippe Denoel, Jan Poolman, Joelle Thonnard
  • Publication number: 20100098729
    Abstract: The present invention relates to a surface exposed protein, which can be detected in Moraxella catarrhalis, having an amino acid sequence as described in SEQ ID NO: 1, an apparent molecular weight of 200 kDa and a capacity of selectively binding membrane bound or soluble IgD, to an immunogenic or IgD-binding fragment of said surface exposed protein, and to an immunogenic and adhesive fragment of said surface exposed protein. DNA segments, vaccines, plasmids and phages, non human hosts, recombinant DNA molecules and plants, fusion proteins and polypeptides and fusion products are also described. A method of detecting IgD, a method of separating IgD, a method of isolation of a surface exposed protein of Moraxella catarrhalis and a method for treatment of an autoimmune disease are also disclosed.
    Type: Application
    Filed: May 21, 2008
    Publication date: April 22, 2010
    Applicant: ARNE FORSGREN ET AL.
    Inventors: Arne Forsgren, Kristian Riesbeck, Håkan Jansson
  • Patent number: 7691395
    Abstract: The invention provides BASB119 polypeptides and polynucleotides encoding BASB119 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: April 6, 2010
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: Joelle Thonnard
  • Publication number: 20100062027
    Abstract: The present invention relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present invention also provides peptides interacting with fibronectin, laminin and the complement system.
    Type: Application
    Filed: August 8, 2006
    Publication date: March 11, 2010
    Inventors: Arne Forsgren, Kristian Riesbeck
  • Patent number: 7641910
    Abstract: The invention provides BASB027 polypeptides and polynucleotides encoding BASB027 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: January 5, 2010
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: Carlota Vinals y de Bassols
  • Patent number: 7641906
    Abstract: The invention relates to intranasal immunization with detoxified lipooligosaccharide from nontypeable Haemophilus influenzae or Moraxella catarrhalis.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: January 5, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Xin-Xing Gu
  • Patent number: 7632516
    Abstract: The invention provides BASB115 polypeptides and polynucleotides encoding BASB115 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: December 15, 2009
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: Joelle Thonnard
  • Publication number: 20090246228
    Abstract: Novel antigens of B. catarrhalis are provided, together with their use in vaccines as well as methods of diagnosing and/or detection.
    Type: Application
    Filed: June 8, 2009
    Publication date: October 1, 2009
    Inventors: Allan William CRIPPS, Jennelle Kyd
  • Publication number: 20090214537
    Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.
    Type: Application
    Filed: May 12, 2006
    Publication date: August 27, 2009
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Marco Soriani, Isabella Santi
  • Patent number: 7470432
    Abstract: The present invention relates to a surface exposed protein, which can be detected in Moraxella catarrhalis, having an amino acid sequence as described in SEQ ID NO 1, an apparent molecular weight of 200 kDa and a capacity of selectively binding membrane bound or soluble IgD, to an immunogenic or IgD-binding fragment of said surface exposed protein, and to an immunogenic and adhesive fragment of said surface exposed protein. DNA segments, vaccines, plasmids and phages, non human hosts, recombinant DNA molecules and plants, fusion proteins and polypeptides and fusion products are also described. A method of detecting IgD, a method of separating IgD, a method of isolation of a surface exposed protein of Moraxella catarrhalis and a method for treatment of an autoimmune disease are also disclosed.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: December 30, 2008
    Assignee: Arne Forsgren et al
    Inventors: Arne Forsgren, Kristian Riesbeck, Håkan Jansson
  • Patent number: 7432366
    Abstract: Provided are Moraxella catarrhalis BASB034 polypeptides and immunogenic fragments of BASB034 polypeptides. Preferably, the immunogenic fragments have at least 15 amino acids that match an aligned contiguous segment of SEQ ID NOs:2, 4, 6 or 8. The immunogenic fragments, when administered to a subject in a suitable composition (which can include an adjuvant, or a suitable carrier coupled to the fragment) raise an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:2, 4, 6 or 8. The invention further provides immunogenic compositions containing BASB034 polypeptides and immunogenic fragments thereof, and a pharmaceutically acceptable carrier. Also provided are fusion proteins that contain BASB034 polypeptides and immunogenic fragments thereof.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: October 7, 2008
    Assignee: SmithKline Beecham Biologicals S.A.
    Inventor: Jean-Louis Ruelle
  • Patent number: 7410648
    Abstract: The present invention relates to polypeptides, more particularly polypeptides of Moraxella (Branhamella) catarrhalis which may be used to prevent, diagnose and/or treat Moraxella (Branhamella) catarrhalis infection.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: August 12, 2008
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Josée Hamel, Bernard R. Brodeur, Stéphane Rioux, Julie Couture
  • Publication number: 20080160045
    Abstract: To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can reduce antigen hydrolysis. Histidine is preferably present during adsorption to the aluminum salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably from N. meningitidis.
    Type: Application
    Filed: January 3, 2008
    Publication date: July 3, 2008
    Applicant: Novartis Vaccines and Diagnostics, s.r.l.
    Inventors: Mario Contorni, Massimo Maffei
  • Patent number: 7344724
    Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: March 18, 2008
    Assignees: Board of Regents, The University of Texas System, Wyeth Holdings Corporation
    Inventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
  • Patent number: 7329500
    Abstract: The present invention relates to polypeptides of Moraxella (Branhamela) catarrhalis which may be used for prophy-laxis, diagnostic and/or therapy purposes.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: February 12, 2008
    Assignee: ID Biomedical Corporation
    Inventors: Denis Martin, Josée Hamel, Bernard R. Brodeur, Stéphane Rioux, Julie Couture
  • Patent number: 7311917
    Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to M. catarrhalis and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: December 25, 2007
    Assignee: Emergent Product Development Gaithersburg, Inc.
    Inventors: Kenneth Tucker, Ulrich F. Tillmann
  • Patent number: 7241449
    Abstract: Purified and isolated nucleic acid molecules are provided which encode Tbp2 proteins of M. catarrhalis strains M35, 3 and LES1. The nucleic acid sequence may be used to produce recombinant Tbp2 proteins of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules may be used in the diagnosis of infection.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: July 10, 2007
    Assignee: Aventis Pasteur Limited
    Inventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
  • Patent number: 7128910
    Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding OMP106 polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses to M. catarrhalis and M. catarrhalis OMP106 polypeptides and OMP106-derived polypeptides in animals.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: October 31, 2006
    Assignee: Emergent Product Development Gaithersburg Inc.
    Inventors: Kenneth Tucker, Laura Plosila
  • Patent number: 7122197
    Abstract: The invention provides BASB020 polypeptides and polynucleotides encoding BASB020 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: October 17, 2006
    Assignee: SmithKline Beecham Biologicals S.A.
    Inventor: Joelle Thonnard
  • Patent number: 7018639
    Abstract: The present invention relates to antigens of Moraxella, in particular, Moraxella bovis, nucleic acid sequences encoding these antigens and formulations for use in raising an immune response against Moraxella.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: March 28, 2006
    Assignees: Commonwealth Scientific and Industrial Research Organisation, The University of Melbourne
    Inventors: Jacinta Farn, Richard Strugnell, Jan Tennent
  • Patent number: 6951652
    Abstract: A vaccine is disclosed which is useful for protecting a host from Gram negative infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepared by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7; (b) (AB)m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and (c) (ABC)p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: October 4, 2005
    Assignee: BioSynth S.r.l.
    Inventor: Massimo Porro
  • Patent number: 6921537
    Abstract: Described herein is a method for removing toxic lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis. LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: July 26, 2005
    Assignee: Wyeth
    Inventor: Gary W. Zlotnick
  • Patent number: 6899885
    Abstract: A protein from M. catarrhalis, designated the 74 kD protein, is isolated and purified. The 74 kD protein has an amino-terminal amino acid sequence which is conserved among various strains of M. catarrhalis. The protein has a molecular weight of approximately 74.9 kD as measured on a 10% SDS-PAGE gel, while its molecular weight as measured by mass spectrometry is approximately 74 kD. The 74 kD protein is used to prepare a vaccine composition which elicits a protective immune response in a mammalian host, to protect the host against disease caused by M. catarrhalis.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: May 31, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Dexiang Chen, Karl R. VanDerMeid, John C. McMichael, Vicki L. Barniak
  • Patent number: 6858211
    Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-D-GalpNAc-(1?2)-?-D-PerpNAc-(1?3)-?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.
    Type: Grant
    Filed: July 20, 1998
    Date of Patent: February 22, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Shousun Chen Szu, John B. Robbins, Yvonne Ageyman Konadu, Edward Konadu
  • Patent number: 6805868
    Abstract: The invention provides BASB109 polypeptides and polynucleotides encoding BASB109 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: October 19, 2004
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: Joelle Thonnard
  • Patent number: 6803043
    Abstract: The invention provides BASB027 polypeptides and polynucleotides encoding BASB027 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: October 12, 2004
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: Carlota Vinals y de Bassols
  • Patent number: 6770459
    Abstract: The invention provides BASB081 polypeptides and polynucleotides encoding BASB081 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: January 28, 2002
    Date of Patent: August 3, 2004
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventor: Jean-Louis Ruelle
  • Patent number: 6764834
    Abstract: The invention provides BASB019 polypeptides and polynucleotides encoding BASB019 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: July 20, 2004
    Assignee: SmithKline Beecham Biologicals, s.a.
    Inventor: Jean-Louis Ruelle
  • Patent number: 6706271
    Abstract: The invention provides BASB023 polypeptides encoding BASB023 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: March 16, 2004
    Assignee: SmithKline Beecham Biologicals s.a.
    Inventor: Joelle Thonnard
  • Patent number: 6706269
    Abstract: The invention provides BASB031 polypeptides and polynucleotides encoding BASB031 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: March 16, 2004
    Assignee: SmithKline Beecham Biologicals s.a.
    Inventors: Jean-Louis Ruelle, Carlota Vinals Y De Bassols
  • Patent number: 6706494
    Abstract: The invention provides BASB028 polypeptides and polynucleotides encoding BASB028 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: March 16, 2004
    Assignee: SmithKline Beecham Biologicals s.a.
    Inventor: Jean-Louis Ruelle
  • Patent number: 6685949
    Abstract: A conjugate vaccine for Moraxella (Branhamella) catarrhalis comprising isolated lipooligosaccharide from which esterified fatty acids have been removed, to produce a detoxified lipooligosaccharide (dLOS), or from which lipid A has been removed, to produce a detoxified oligosaccharide (OS), which is linked to an immunogenic carrier. The vaccine is useful for preventing otitis media and respiratory infections caused by M. catarrhalis in mammals, including humans.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: February 3, 2004
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Xin-Xing Gu, John B. Robbins